Etanercept is a protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis. Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.
- Mechanism
- Curator reviewed · 3 references
There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55). Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. Notably, etancerpt is only capable of binding to the active trimeric form of TNF as its binding site is located in the cleft between subunits. TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Increased levels of TNF are found in tissues and fluids of those with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
- Primary indication
- Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older.Curator reviewed · 22 structured indications
- Formula / weight
- C2224H3475N621O698S36 · 51234.9 Da (Monomer)
- First approval
- Canada, 2000 · United States, 2003 · European Union, 2016
- Also known as
- etanercept-szzs · etanercept-ykro · Recombinant human TNF · rhu TNFR:Fc · rhu-TNFR:Fc
- Code names
- CHS-0214 · DWP-422 · ENIA-11 · GP-2015 · GP2015C · HD-203 · LBEC-0101 · SB-4
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Etanercept, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account